The differentiation within the Anti-nuclear Antibody Testing Market Segment is heavily influenced by the specific clinical requirements of the end-user. The primary care and general screening segment, which accounts for the largest volume of tests, typically prioritizes cost-effectiveness and high throughput, driving demand for automated ELISA or CLIA-based screening platforms. For this...